Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 31

Trial Status

Recruiting2
Other3

Role Distribution

Principal Investigator5
PI Rate100%

Activity Timeline

Clinical Trials (5)

NCT07477015Recruiting
Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune Encephalitis
Autoimmune Encephalitis
PrincipalinvestigatorStart date: 2025-07-31
NCT06906692Active Not Recruiting
Meningococcal Vaccination in Patients on Complement Inhibitors
Complement SystemMyasthenia Gravis GeneralisedNeuromyelitis Optica Spectrum Disease (NMOSD)+1 more
PrincipalinvestigatorStart date: 2025-03-25
Markers of Favorable Response to FcRn Inhibitors(INFORM)
Myasthenia Gravis Generalized
PrincipalinvestigatorStart date: 2024-07-09
NCT06455709Recruiting
Markers of Favorable Response to Complement Inhibitors Therapy
Myasthenia Gravis, Generalized
PrincipalinvestigatorStart date: 2024-06-05
NCT05868837Phase 3Unknown
Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
Myasthenia Gravis, Generalized
PrincipalinvestigatorStart date: 2022-02-28

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Publications (0)

No publications found for this investigator.

Clinical Trials (5)

Showing 5 of 5 trials

NCT07477015PrincipalInvestigator

Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune Encephalitis

Autoimmune Encephalitis
Recruiting
NCT06906692PrincipalInvestigator

Meningococcal Vaccination in Patients on Complement Inhibitors

Complement SystemMyasthenia Gravis GeneralisedNeuromyelitis Optica Spectrum Disease (NMOSD)+1 more
Active Not Recruiting
NCT06685055PrincipalInvestigator

Markers of Favorable Response to FcRn Inhibitors(INFORM)

Myasthenia Gravis Generalized
Unknown
NCT06455709PrincipalInvestigator

Markers of Favorable Response to Complement Inhibitors Therapy

Myasthenia Gravis, Generalized
Recruiting
NCT05868837Phase 3PrincipalInvestigator

Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)

Myasthenia Gravis, Generalized
Unknown

All 5 trials loaded